Zacks small cap research.

19 May 2013 ... Zacks is a hoax. Top rated stocks become low rated stock very quickly. Out of approximately 20 top pick I had two that made money and all ...David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other …Aug 24, 2023 · By Lisa Thompson OTC:NEXCF CSE:TGGL READ THE FULL NEXCF RESEARCH REPORT Nextech (OTC:NEXCF) reported Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. The company had preannounced this number on August 1st. Investors are still awaiting news that Nextech’s 3D modeling services will be available to merchants in Amazon’s Seller Central which is expected to boost

1. Strong Balance Sheet – MediciNova exited the first quarter of 2023 with approximately $55.3 million in cash and cash equivalents. Due to a low operating cash burn rate, we estimate this is enough to fund operations for at least the next four years. The financial markets continue to be difficult for small-cap biotech companies, and those ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Aug 17, 2023 · The following slide gives an overview of the planned early stage clinical trials for CF-370 following submission of the IND, which we expect to occur in the third quarter of 2023. While a Phase 2 proof-of-concept trial is currently planned in patients with cystic fibrosis, the broad spectrum activity of CF-370 means it could likely be used for ... Zacks Investment Research is a leading provider of independent investment research with a proven track record of outperforming the market.

Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 1, 2021 Raising …1. Source: Created by Zacks Small Cap Research Analysts. By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX …By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)06/12/2023. UHAL: U-Haul Holding Company Reports Financial Results for Fiscal 2023; Demand for truck rentals slowed in the second half of FY2023. Management aspires to hold the market share gains and has expectations that the self-moving market will stabilize in FY2024. 06/08/2023.

Zacks Small-Cap Research Tom Kerr 312-265-9147 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 November 14, 2022 UPDATE: Siyata reported 2022 3rd quarter financial results which showed high revenue growth rates compared to the prior year period. Utilizing a DCF valuation process containing

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

By John Vandermosten, CFA. NYSE:NHWK. READ THE FULL NHWK RESEARCH REPORT. The recently renamed NightHawk Biosciences, Inc. (NYSE:NHWK) reported first quarter 2022 results on May 16, 2022 and filed its Form 10-Q with the SEC. It has been a whirlwind year for the company as it made an acquisition, expanded its …'Who needs breadth when we have Nvidia's beat?': We've been here before, and I can tell you it lasts longer than it should. Let's look at charts and indicators, past and present....NVDA We're in that part of the cycle wh...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …May 23, 2023 · A date for the Adcom has not been announced yet. This news follows the company’s Type A meeting with the FDA in early January 2023 to discuss the refusal to file letter (RTF) that the company received in November 2022. The RTF letter made the BLA inactive and the FDA offered multiple options for BrainStorm to pursue to re-activate the BLA. SCR Premium. Receive Initiation Reports PROMPTLY as they are sent out to the marketplace. Access the FULL REPORT CATALOG on any company we cover. Receive the DAILY ALERT EMAIL, containing all of the day's updates, around 5 p.m. EST. Access to REAL-TIME EMAIL ALERTS for any companies covered by Zacks SCR analysts.. …Forgot your password? Email us at [email protected] for assistance ...Oct 31, 2023 · Fund Description. The fund was incepted in May 2000 and is managed by Franklin Advisers. The objective of this fund is long-term capital growth. The fund invests at least 80% of its net assets in ...

Zacks Rank N/A INBS: Australia Off to a Strong Start Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 5, 2023 312-265-9588 / [email protected] ESTIMATES Revenue ns of USD) Q1 Q2 Q3 Q4 Year Jul 31, 2023 · Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers. By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ...ZACKS SMALL/MID CAP ETF. The Zacks Small/Mid Cap ETF seeks to generate consistent and sustainable returns while minimizing the risk of capital …$30.59 USD -0.17 (-0.55%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of …

RVLP: Bright-Eyed and Bushy-Tailed. 04/10/2023. By John Vandermosten, CFA. NASDAQ:RVLP. The Journal of Plastic, Reconstructive and Aesthetic Surgery published an article entitled The Effect of Topical Oxymetazoline on Eyelid Position, Eye Redness, and Patient-Reported Eye Appearance: A Randomized Controlled Trial.

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT First Quarter 2023 Results MiMedx Group, Inc. (NASDAQ:MDXG) reported first quarter 2023 revenues of $71.7 million, representing a 22% year over year growth rate, surpassing our $64.2 million estimate. Loss from operations was ($3.4) million, …The small-cap index Russell 2000 recently witnessed its most impressive week in over two years as investors bet on the Federal Reserve's halt in its interest rate …Put on Your Rally Cap, as We Turn the Last Two Inside-Out Do you get the sense that folks were more bullish after last Wednesday's rally than they were after Monday's rally? That's the sense I get. I suppose that is because last week's rug ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 knows the company well, in our view.Apr 26, 2023 · By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update First Patient Dosed in Phase 1b/2 Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On April 26, 2023, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 1b/2 clinical trial of exebacase in the setting of a minimally-invasive arthroscopic debridement, antibiotics, 2 days ago · This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

How many stars would you give Zacks Investment Research? Join the 86 people who've already contributed. Your experience matters.

In today’s digital age, having a reliable and fast internet connection is essential. When searching for an internet provider, you may come across terms like “unlimited data” and “data caps.” Understanding these terms is crucial to ensure yo...

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO-MUC5AC, which are the company’s investigational candidates designed as potential treatmentsExpense Ratio 1.390%. Distribution Fee Level High. Share Class Type No Load. Category Small Blend. Investment Style Small Blend. Min. Initial Investment 2,500. Status Open. TTM Yield 0.47% ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Yes, absolutely. Zacks is worth it. Given that the stocks they rate as a #1 Strong Buy have beat the SP500 by 13.9% on average for the last 34 years, their system works. And the fact that the stocks they rate as a #5 Strong Sell have underperformed the market by 8.4% all but proves their system.Jan 5, 2023 · By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND) Zacks Small-Cap Research Sponsored – Impartial – Comprehensive November 8, 2023 John D. Vandermosten, CFA scr.zacks.com 312-265-9588 / [email protected] …16 Feb 2022 ... With Sharesight, investors can get Zacks Investment Research news directly in their portfolio for US stocks. ... Small Caps and ausbiz. Sharesight ...MIRA Continues to Pursue New Pain Relief. 11/14/2023. By Brad Sorensen, CFA. NASDAQ:MIRA. READ THE FULL MIRA RESEARCH REPORT. MIRA (NASDAQ:MIRA) reported 3Q earnings of -$0.26 per share as it...Zacks Small-Cap Research Sponsored – Impartial - Comprehensive Lisa Thompson 312-265-9517 [email protected] Sponsored – Impartial - Comprehensive …David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...By John Vandermosten, CFA. NYSE:NHWK. READ THE FULL NHWK RESEARCH REPORT. The recently renamed NightHawk Biosciences, Inc. (NYSE:NHWK) reported first quarter 2022 results on May 16, 2022 and filed its Form 10-Q with the SEC. It has been a whirlwind year for the company as it made an acquisition, expanded its …

Zacks Small-Cap Research Sponsored – Impartial - Comprehensive Lisa Thompson 312-265-9517 [email protected] Sponsored – Impartial - Comprehensive …Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ...May 30, 2023 · Zacks Small Cap Research. PLX: Back of the Envelope. Read full article. 1. Zacks Small Cap Research. May 30, 2023 at 8:00 AM ... Zacks Rank N/A Third Quarter Update Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 November 15, 2021 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec)Instagram:https://instagram. amazon cars for salewhat are safe stocks to invest inetf channelwhere can i buy stocks in canada Oct 17, 2022 · By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT Uxin Limited (NASDAQ:UXIN) operates a leading e-commerce platform for buying and selling used cars in China. The company also has two physical locations where customers can view and purchase cars in person. The company has recently transitioned to an inventory-owning model which provides customers with a comprehensive transaction best luxury watch insurancetop books on accounting SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting … moving stocks today Giles Haycock Managing Director (T) 312.265.9351 (M) 312.752.6718 (F) 312.265.9560 (E) [email protected] Twitter: @ZacksSmallCap Steven Ralston, CFA Director of ResearchDIREXION DAILY SMALL CAP BULL 3X SHARES. The Direxion Daily Small Cap Bull 3x Shares seeks daily investment results, before fees and expenses, of 300% of the performance of the Russell 2000 Index ...By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)